Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.
Neuronal nicotinic acetylcholine receptors (nAChRs) are critical for higher order cognitive processes. Post-mortem studies suggest reductions in nAChRs (particularly the alpha(4)beta(2) subtype) with ageing and in Alzheimer's disease (AD). This study aimed to; (1) quantify nAChR distribution in vivo with 2-[18F]fluoro-A-85380 (2-FA) in 15 early AD patients compared to 14 age-matched, healthy controls (HC) and (2) correlate nAChR distribution with cognitive performance in both groups. All participants were non-smokers and underwent cognitive testing along with a dynamic PET scan after injection of 200 MBq of 2-FA. Brain regional 2-FA binding was assessed through a simplified estimation of Distribution Volume (DV(S)). The AD group differed significantly from HC on all cognitive measures employed, with impairments on measures of attention, working memory, language, executive function, visuospatial ability, verbal learning and verbal memory (p<.05). Contrary to post-mortem data this study found no evidence of in vivo nAChR loss in early AD despite significant cognitive impairment. Furthermore, no correlation between nAChR and cognitive performance was found for either group. The findings of the current study suggest preservation of nAChRs early in AD supporting previous studies. It is possible that while the clinical 2-FA PET method described here may be insensitive in detecting changes in early AD, such changes may be detected in more advanced stages of the illness.
Ellis
J R
JR
Department of Nuclear Medicine and Centre for PET, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia. ellis@petnm.unimelb.edu.au
Villemagne
V L
VL
Nathan
P J
PJ
Mulligan
R S
RS
Gong
S J
SJ
Chan
J G
JG
Sachinidis
J
J
O'Keefe
G J
GJ
Pathmaraj
K
K
Wesnes
K A
KA
Savage
G
G
Rowe
C C
CC
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000145:classification / Q000000981:diagnostic imaging*; D001288:Attention / Q000502:physiology; D001921:Brain / Q000000981:diagnostic imaging; D002755:Choice Behavior / Q000502:physiology; D003072:Cognition Disorders / Q000000981:diagnostic imaging*; D004193:Discrimination Learning / Q000502:physiology; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007266:Inhibition, Psychological; D008279:Magnetic Resonance Imaging; D008297:Male; D008570:Memory, Short-Term / Q000502:physiology; D008875:Middle Aged; D009483:Neuropsychological Tests; D009949:Orientation / Q000502:physiology; D049268:Positron-Emission Tomography; D011340:Problem Solving / Q000502:physiology; D011597:Psychomotor Performance / Q000502:physiology; D011725:Pyridines; D011930:Reaction Time / Q000502:physiology; D011978:Receptors, Nicotinic / Q000502:physiology*; D014706:Verbal Learning / Q000502:physiology
C499325:2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine; D005462:Fluorine Radioisotopes; D011725:Pyridines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2